{"denoms":[{"counts":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"234"},{"groupId":"BG002","value":"472"}],"units":"Participants"}],"groups":[{"description":"Participants received 300 mg azacitidine tablets once a day (QD) for the first 14 days of each 28-day treatment cycle until discontinuation, which includes the following reasons: disease relapse, withdrawal of consent, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, death, lost to follow-up, or protocol violation or until the end of the study.","id":"BG000","title":"Oral Azacitidine Plus Best Supportive Care"},{"description":"Participants received identically matching placebo tablets QD for the first 14 days of each 28-day treatment cycle until no longer receiving benefit, withdrawal of consent, disease relapse, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, lost to follow-up, or protocol violation or until the end of the study.","id":"BG001","title":"Placebo Plus Best Supportive Care"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"5.72","value":"67.9"},{"groupId":"BG001","spread":"5.62","value":"68.0"},{"groupId":"BG002","spread":"5.66","value":"67.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"134"}],"title":"18 to 64 Years"},{"measurements":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"166"},{"groupId":"BG002","value":"337"}],"title":"65 to 84 Years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"≥ 85 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"227"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"127"},{"groupId":"BG002","value":"245"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"34"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"196"},{"groupId":"BG001","value":"202"},{"groupId":"BG002","value":"398"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"40"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"216"},{"groupId":"BG001","value":"197"},{"groupId":"BG002","value":"413"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"}],"title":"Black or African-American"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"26"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"23"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Missing"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"85"}],"title":"AML with Recurrent Genetic Abnormalities"},{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"91"}],"title":"AML with Myelodysplasia - Related Changes"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Therapy-related Myeloid Neoplasms"},{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"293"}],"title":"AML not Otherwise Specified"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Missing"}]}],"description":"AML is classified using the WHO classification system based upon a combination of morphology, immunophenotype, genetics, and clinical features. There are several broad groups and include: 1. AML with genetic abnormalities; 2. AML with multilineage dysplasia 3. AML related to previous chemotherapy or radiation 4. Unspecified AML - do not fall into the above groups","paramType":"COUNT_OF_PARTICIPANTS","title":"Initial Acute Myeloid Leukemia (AML) Classification","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"213"},{"groupId":"BG001","value":"216"},{"groupId":"BG002","value":"429"}],"title":"Primary (de novo)"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"43"}],"title":"Secondary"}]}],"description":"Primary AML is a cancer that originates in the blood and bone marrow. AML affects a group of white blood cells called myeloid cells, which normally develop into the various types of mature blood cells, such as red blood cells, white blood cells and platelets. Secondary acute myeloid leukemia (s-AML) refers to a leukemic process: (1) evolving from prior myelodysplasia (MDS), myeloproliferative disorder (MPN), or aplastic anemia (AA) with or without treatment or (2) as a product of previous exposure to a proven leukemogenic chemotherapeutic agent (therapy-related AML \\[t-AML\\]).","paramType":"COUNT_OF_PARTICIPANTS","title":"Type of Acute Myeloid Leukemia (AML)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"203"},{"groupId":"BG002","value":"406"}],"title":"Intermediate"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"66"}],"title":"Poor"}]}],"description":"Cytogenetic Risk - Intermediate -I is of a normal karyotype; Poor Risk - includes complex karyotypes having 3 or more cytogenetic abnormalities.","paramType":"COUNT_OF_PARTICIPANTS","title":"Cytogenetic Risk Category at Diagnosis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"116"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"227"}],"title":"Grade 0"},{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"207"}],"title":"Grade 1"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"36"}],"title":"Grade 2"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Grade 3"}]}],"description":"ECOG performance status is used to describe a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). The scale ranges from 0 to 5: 0 = Fully active, no restrictions; 1 = Restricted activity but ambulatory, able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities; 3 = Capable to only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled, no self-care, confined to bed or chair; 5 = Dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"The intent to treat (ITT) population includes participants who were randomized, regardless of whether they received treatment or not."}